Drug Profile
SB 400 family - Symic Bio
Alternative Names: SB-400Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator SYMIC Biomedical
- Developer Symic Bio
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Multiple sclerosis
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
- 28 Sep 2020 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 11 Aug 2016 Early research in Amyotrophic lateral sclerosis in USA (unspecified route)